This article reviews the results of the rigorously-controlled clinical trial focusing on the use of copolymer-1 in the treatment of patients with relapsing-remitting MS.
Copolymer-1 (Copaxone[R]), is an acetate salt resulting from a mixture of synthetic polypeptides composed of the four amino acids L-alanine L-glutamic acid, L-lysine and L-tyrosine.
Copolymer-1 was first synthesized in 1967, and was studied extensively in animal models.
Copolymer-1 was studied by Johnson et al in 1995, in a multicenter, phase III trial of patients with relapsing-remitting multiple sclerosis.
Patients who had been treated with copolymer-1 or any other immuno-suppressive therapy, chemotherapy or lymphoid irradiation were also excluded.
Nurses are in a unique position to give patients taking copolymer-1 advice about medication administration and storage, adverse effects, psychological/psychosocial issues, as well as tips for proper administration.
The value of this extension data on the overall clinical picture for Copolymer-1 is significant, given issues impacting currently existing interferon treatment," said Dr.
A study on the effects of Copolymer-1 antibody production was presented at a poster session at the ANA meeting.
The positive result of this trial with excellent patient tolerance and with no evidence to date of a decline in effectiveness due to neutralizing activity, places Copolymer-1 among the agents which may become available in the near future to combat the long-term effects of MS.
These new clinical findings demonstrate the increased effect of Copolymer-1 in altering the course of multiple sclerosis and expand on the compound's overall efficacy and safety profile.
007) for the Phase III 24-month data in patients taking Copolymer-1 compared with those taking placebo.
035) during the extension among those taking Copolymer-1 (33.